Document is current

Article History

Received: 24 October 2025

Accepted: 18 March 2026

First Online: 21 April 2026

Declarations

:

: Enrique Gómez de la Fuente has received speaker honoraria, and support for attending meeting and/or travel from Lilly, Abbvie, Sanofi, Pfizer, and Leo Pharma; and has participated on a data safety monitoring board (DSMB) or advisory board for Lilly, Abbvie, Sanofi, and Pfizer. At the time of the study, Enrique Gómez de la Fuente worked at Hospital Fundación Alcorcón (Madrid, Spain). His current affiliation is Hospital Ramón y Cajal (Madrid, Spain). David Vidal Sarró has received consulting fees and speaker honoraria from Lilly. Ignasi Figueras-Nart has received consulting fees, speaker honoraria, and support for attending meetings and/or travel from Lilly, Novartis, Sanofi, Abbvie, Leo Pharma, Vifor Pharma, and Pfizer. Juan F. Silvestre Salvador has received consulting fees from AbbVie, Almirall-Hermal, Lilly, Galderma, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; speaker honoraria and participated on a DSMB or Advisory Board for AbbVie, Almirall-Hermal, Lilly, Galderma, LEO Pharma, Pfizer and Sanofi-Genzyme; and support for attending meetings and/or travel from AbbVie, Almirall-Hermal, Lilly, Pfizer and Sanofi-Genzyme. Yolanda Gilaberte received consulting fees from Lilly, Cantabria Labs, Leo Pharma, Isdin, UCB and Almirall; received speaker honoraria from Sanofi, Pfizer, Abbvie, Cantabria Labs, Eucerin, Lilly, Leo Pharma and Incyte; support for attending meeting and/or travel from Sanofi and Eucerin; and has acted as leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for the European Academy of Dermatology and Virology (EADV) and the European Society of Photodermatology. Sergio Santos Alarcón has received speaker honoraria, and payment for expert testimony from; and has participated on a DSMB or Advisory Board for Almirall, Abbvie, Amgen, Pfizer, Novartis, Janssen-Cilag, Lilly, Leo Pharma, UCB Pharma, Pierre Fabre, Isdin, and Sanofi. Esther Serra-Baldrich has received grants or contracts from Galderma, Sanofi, Incyte and Leo Pharma; speaker honoraria from Sanofi, Galderma, Pfizer, Abbvie, Lilly and Leo Pharma; support for attending meeting and/or travel from Sanofi and Pfizer; and has participated on a DSMB or Advisory Board for Sanofi, Galderma, Pfizer, Abbvie, Lilly, and Leo Pharma. Rosa M. Moro, Silvia Díaz-Cerezo, Sebastián Moyano and Mercedes Núñez are full time employees at Lilly and minor owners of Lilly shares. Enrique Herrera, Iñigo Martínez-Espronceda Esquerdo, Mónica Munera Campos and Irene Talavera-Rodríguez declare that they have no competing interests.

: The study was designed and conducted in accordance with the ethical principles set out in the Declaration of Helsinki and was approved by the Hospital Universitario Fundación Alcorcón Ethics Committee (Code 23/58). All patients provided written informed consent for the collection of their medical data and its use as part of this observational research study.